COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it—the antiviral drug Paxlovid—is less clear.

Paxlovid, impacting its distribution and use in treating mild-to-moderate COVID-19. In December 2021, the FDA authorized Paxlovid for emergency use for the treatment of adults and pediatric ...

Paxlovid is the most commonly prescribed at home treatment for COVID-19 in the U.S. It is approved to treat COVID in adults who are at risk of severe complications from the illness.

Paxlovid made no significant improvement to long COVID symptoms, including fatigue, brain fog and body aches. The finding “does not rule out” Paxlovid as a therapy, the researchers wrote.

Dr. Astha Muttreja, a physician at the Stony Brook Medicine's post-COVID Clinic in Lake Grove, said there had been “cautious optimism” that Paxlovid would be a potential treatment method for ...

The findings are described in a paper to be published June 7 in JAMA Internal Medicine. Paxlovid is a highly effective antiviral agent licensed for treatment of acute COVID-19.

Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.

FDA researchers estimated, based on Covid rates in January, that Paxlovid could "lead to 1,500 lives saved and 13,000 hospitalizations averted each week" in the U.S.

Most people who take Paxlovid for the treatment of COVID do not get rebound COVID, but up to 20% of patients do. That doesn't mean that the drug isn't doing its job.

As soon as doctors determined on Thursday that President Biden had Covid-19, the White House doctor put him on the antiviral Paxlovid. Considered a game-changer when it was authorized in December ...